Verrica Pharmaceuticals Inc. (VRCA) stock
VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.20−0.36 (-10.11%)
Close on Nov 16, 2026Market cap $54.97MP/E –Yield –
Verrica Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Verrica Pharmaceuticals's cash was $11.20M at Jun 30, 2026. For fiscal 2025 it was $30.15M, up 201.5% from the year before. The highest annual figure on record is $70.40M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.15M | +201.5% |
| FY2024 | Dec 31, 2024 | $10.00M | -85.6% |
| FY2023 | Dec 31, 2023 | $69.55M | +102.9% |
| FY2022 | Dec 31, 2022 | $34.27M | -51.3% |
| FY2021 | Dec 31, 2021 | $70.40M | +558.8% |
| FY2020 | Dec 31, 2020 | $10.69M | +15.6% |
| FY2019 | Dec 31, 2019 | $9.24M | -10.0% |
| FY2018 | Dec 31, 2018 | $10.27M | +18.6% |
| FY2017 | Dec 31, 2017 | $8.66M | +1543.8% |
| FY2016 | Dec 31, 2016 | $527.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.20M | -27.3% |
| Q1 FY2026 | Mar 31, 2026 | $20.60M | +106.0% |
| Q4 FY2025 | Dec 31, 2025 | $30.15M | +201.5% |
| Q3 FY2025 | Sep 30, 2025 | $21.10M | -8.1% |
| Q2 FY2025 | Jun 30, 2025 | $15.40M | -51.8% |
| Q1 FY2025 | Mar 31, 2025 | $10.00M | -79.6% |
| Q4 FY2024 | Dec 31, 2024 | $10.00M | -85.6% |
| Q3 FY2024 | Sep 30, 2024 | $22.96M | -72.8% |
| Q2 FY2024 | Jun 30, 2024 | $31.93M | -42.1% |
| Q1 FY2024 | Mar 31, 2024 | $48.94M | -18.4% |
| Q4 FY2023 | Dec 31, 2023 | $69.55M | +102.9% |
| Q3 FY2023 | Sep 30, 2023 | $84.31M | +113.4% |
| Q2 FY2023 | Jun 30, 2023 | $55.14M | +1.4% |
| Q1 FY2023 | Mar 31, 2023 | $59.95M | -3.1% |
| Q4 FY2022 | Dec 31, 2022 | $34.27M | -51.3% |
| Q3 FY2022 | Sep 30, 2022 | $39.50M | -50.3% |
| Q2 FY2022 | Jun 30, 2022 | $54.40M | +120.2% |
| Q1 FY2022 | Mar 31, 2022 | $61.90M | +40.4% |
| Q4 FY2021 | Dec 31, 2021 | $70.40M | +558.8% |
| Q3 FY2021 | Sep 30, 2021 | $79.50M | +362.3% |
| Q2 FY2021 | Jun 30, 2021 | $24.71M | -49.5% |
| Q1 FY2021 | Mar 31, 2021 | $44.10M | -19.1% |
| Q4 FY2020 | Dec 31, 2020 | $10.69M | +15.6% |
| Q3 FY2020 | Sep 30, 2020 | $17.20M | +62.2% |
| Q2 FY2020 | Jun 30, 2020 | $48.93M | +146.5% |
| Q1 FY2020 | Mar 31, 2020 | $54.49M | +123.1% |
| Q4 FY2019 | Dec 31, 2019 | $9.24M | -10.0% |
| Q3 FY2019 | Sep 30, 2019 | $10.60M | -72.3% |
| Q2 FY2019 | Jun 30, 2019 | $19.85M | -80.8% |
| Q1 FY2019 | Mar 31, 2019 | $24.43M | -11.1% |
| Q4 FY2018 | Dec 31, 2018 | $10.27M | +18.6% |
| Q3 FY2018 | Sep 30, 2018 | $38.31M | +9574.5% |
| Q2 FY2018 | Jun 30, 2018 | $103.15M | +20285.2% |
| Q1 FY2018 | Mar 31, 2018 | $27.49M | +5115.4% |
| Q4 FY2017 | Dec 31, 2017 | $8.66M | – |
| Q3 FY2017 | Sep 30, 2017 | $396.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $506.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $527.00K | – |
See a number that looks wrong?